Research programme: MOR 101 antibodies - MorphoSys
Alternative Names: MOR 101 antibodies (Fab fragment); MOR 101 antibodies research programme - MorphoSys; MOR101Latest Information Update: 01 Aug 2024
At a glance
- Originator MorphoSys
- Class
- Mechanism of Action Intercellular adhesion molecule-1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Burns
Most Recent Events
- 24 Feb 2006 Discontinued - Preclinical for Burns in Germany (unspecified route)
- 16 May 2005 This programme is still in active development - (BioSquare-2005)
- 27 Jun 2003 MOR 101 is available for licensing (http://www.morphosys.com)